OFOlugbeminiyi O. Fadeyi

Olugbeminiyi O. Fadeyi

*This is an algorithmically generated author record based on publicly available information.

Olugbeminiyi O. Fadeyi has a total of 164 co-authors. Here are the top co-authors by number of shared publications:

  • Rob C. Oslund

    Exploratory Science Center, Merck & Co., Inc., Cambridge, USA

    18 shared publications
  • Keun Ah Ryu

    Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States

    9 shared publications
  • Tyler J. Bechtel

    Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States

    7 shared publications
  • Cory H. White

    Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA

    6 shared publications
  • Erik C. Hett

    Merck Exploratory Science Center, Merck & Co., Inc, Cambridge, MA 02141, USA

    6 shared publications
  • Tamara Reyes-Robles

    Merck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States

    6 shared publications

Latest Publications

  • Open Access

    Proximity-guided graph learning reveals tumour-associated proximity antigens

    by Cody Scandore, Clare F. Malone, Christopher K. May, Anna K. de Regt, Jeff Guernsey, Hayley Ma, Noah Dephoure, Ben Setter, Rebecca A. Howell, Kendall R. Johnson, et al.

    The spatial organization of membrane proteins is an underexplored dimension of cell surface biology1,2. Spatial proximity shapes cellular function and therapeutic targetability2,3, yet efforts to identify tumour-associated antigens (TAAs) have largely focused on expression alone4. Here, we developed an industrialized surface protein proximity-mapping workflow to interrogate TAAs within their membrane microenvironments. Using this workflow, we generated 248 proximity maps across 12 receptor tyrosine kinases and 28 tumour cell systems. The resulting atlas enabled the development of MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers conserved proximity relationships among non-targeted proteins, and establishes the concept of tumour-associated proximity antigens (TAPAs), a class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Integrating these proximity-derived relationships within a multimodal prioritization framework, we identified and validated EGFR–CDCP1 as a TAA–TAPA pair that enhances tumour cell killing across therapeutic modalities. Together, this work advances disease-associated membrane proximity as a guiding principle for the design of precision multispecific therapeutics.


  • Open Access

    Proximity-Informed Graph Learning Defines Spatial Protein Communities for Tumor-Associated Proximity Antigen Discovery

    by Cody Scandore, Clare F. Malone, Christopher K. May, Anna K. de Regt, Jeff Guernsey, Hayley Ma, Noah Dephoure, Ben Setter, Rebecca A. Howell, Kendall R. Johnson, et al.

    The spatial organization of membrane proteins is an underexplored dimension of cell-surface biology. Spatial proximity shapes cellular function and therapeutic targetability, yet efforts to identify tumor-associated antigens (TAAs) have largely focused on expression alone. Here, we developed an industrialized surface-protein proximity mapping workflow to interrogate TAAs within their membrane microenvironments. In the process, we generated 248 proximity maps across 12 receptor tyrosine kinases (RTKs) and 28 tumor cell systems. This proximity atlas enabled two advances: first, MetaMap, a correlation-based analytical framework that defines spatial protein communities and infers non-targeted proximal proteins from reproducible proximity signatures; and second, tumor-associated proximity antigens (TAPAs), a conceptual class of co-targets defined by disease-specific spatial proximity to TAAs rather than expression alone. Applying these proximity-derived relationships within a multimodal prioritization framework, we identified and validated an EGFR×CDCP1 TAA-TAPA pair that enhanced tumor cell killing across therapeutic modalities. By integrating spatial organization with multimodal data, this work expands the design space for precision-guided therapeutic strategies.

  • Therapeutic potential of cis-targeting bispecific antibodies

    by Rob C. Oslund, Pamela M. Holland, Scott A. Lesley, Olugbeminiyi O. Fadeyi


  • Near-Infrared Photoredox Catalyzed Fluoroalkylation Strategy for Protein Labeling in Complex Tissue Environments

    by Keun Ah Ryu, Keun Ah Ryu, Tamara Reyes-Robles, Tamara Reyes-Robles, Thomas P. Wyche, Thomas P. Wyche, Tyler J. Bechtel, Tyler J. Bechtel, Jayde M. Bertoch, Jayde M. Bertoch, et al.


  • Open Access

    In This Issue

    by Olugbeminiyi O. Fadeyi

  • High-resolution photocatalytic mapping of SARS-CoV-2 spike interactions on the cell surface

    by Suprama Datta, Da-Yuan Chen, Alexander H. Tavares, Tamara Reyes-Robles, Keun Ah Ryu, Nazimuddin Khan, Tyler J. Bechtel, Jayde M. Bertoch, Cory H. White, Daria J. Hazuda, et al.


  • μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping

    by Sean W. Huth, James V. Oakley, Ciaran P. Seath, Jacob B. Geri, Aaron D. Trowbridge, Dann L. Parker, Frances P. Rodriguez-Rivera, Adam G. Schwaid, Carlo Ramil, Keun Ah Ryu, et al.

    The characterization of ligand binding modes is a crucial step in the drug discovery process and is especially important in campaigns arising from phenotypic screening, where the protein target and binding mode are unknown at the outset. Elucidation of target binding regions is typically achieved by X-ray crystallography or photoaffinity labeling (PAL) approaches; yet, these methods present significant challenges. X-ray crystallography is a mainstay technique that has revolutionized drug discovery, but in many cases structural characterization is challenging or impossible. PAL has also enabled binding site mapping with peptide- and amino-acid-level resolution; however, the stoichiometric activation mode can lead to poor signal and coverage of the resident binding pocket. Additionally, each PAL probe can have its own fragmentation pattern, complicating the analysis by mass spectrometry. Here, we establish a robust and general photocatalytic approach toward the mapping of protein binding sites, which we define as identification of residues proximal to the ligand binding pocket. By utilizing a catalytic mode of activation, we obtain sets of labeled amino acids in the proximity of the target protein binding site. We use this methodology to map, in vitro, the binding sites of six protein targets, including several kinases and molecular glue targets, and furthermore to investigate the binding site of the STAT3 inhibitor MM-206, a ligand with no known crystal structure. Finally, we demonstrate the successful mapping of drug binding sites in live cells. These results establish μMap as a powerful method for the generation of amino-acid- and peptide-level target engagement data.


  • An electroaffinity labelling platform for chemoproteomic-based target identification

    by Yu Kawamata, Keun Ah Ryu, Gary N. Hermann, Alexander Sandahl, Julien C. Vantourout, Aleksandra K. Olow, La-Tonya A. Adams, Eva Rivera-Chao, Lee R. Roberts, Samer Gnaim, et al.

    Target identification involves deconvoluting the protein target of a pharmacologically active, small-molecule ligand, a process that is critical for early drug discovery yet technically challenging. Photoaffinity labelling strategies have become the benchmark for small-molecule target deconvolution, but covalent protein capture requires the use of high-energy ultraviolet light, which can complicate downstream target identification. Thus, there is a strong demand for alternative technologies that allow for controlled activation of chemical probes to covalently label their protein target. Here we introduce an electroaffinity labelling platform that leverages the use of a small, redox-active diazetidinone functional group to enable chemoproteomic-based target identification of pharmacophores within live cell environments. The underlying discovery to enable this platform is that the diazetidinone can be electrochemically oxidized to reveal a reactive intermediate useful for covalent modification of proteins. This work demonstrates the electrochemical platform to be a functional tool for drug-target identification.


  • Open Access

    Targeted proximity-labelling of protein tyrosines via flavin-dependent photoredox catalysis with mechanistic evidence for a radical–radical recombination pathway

    by Taylor O. Hope, Tamara Reyes-Robles, Keun Ah Ryu, Steven Mauries, Nicole Removski, Jacinthe Maisonneuve, Rob C. Oslund, Olugbeminiyi O. Fadeyi, Mathieu Frenette

    Flavin-based photocatalysts such as riboflavin tetraacetate (RFT) serve as a robust platform for light-mediated protein labelling via phenoxy radical-mediated tyrosine–biotin phenol coupling on live cells. To gain insight into this coupling reaction, we conducted detailed mechanistic analysis for RFT-photomediated activation of phenols for tyrosine labelling. Contrary to previously proposed mechanisms, we find that the initial covalent binding step between the tag and tyrosine is not radical addition, but rather radical–radical recombination. The proposed mechanism may also explain the mecha-nism of other reported tyrosine-tagging approaches. Competitive kinetics experiments show that phenoxyl radicals are generated with several reactive intermediates in the proposed mechanism—primarily with the excited riboflavin-photocatalyst or singlet oxygen—and these multiple pathways for phenoxyl radical generation from phenols increase the likelihood of radical–radical recombination.